Suboxone

DRUG9 trials

Conditions

Cocaine-related DisordersHepatitis CHivModerate to Severe Opioid Use DisorderOpiate AddictionOpioid AddictionOpioid DependenceOpioid Related Disorders

Phase 1

Buprenorphine Naltrexone-P1 A-Cocaine

CompletedNCT00733720

National Institute on Drug Abuse (NIDA)Cocaine-related Disorders

Start: 2008-08-31End: 2009-01-31Target: 8Updated: 2017-01-12

Single Ascending Dose Study of RBP-6000

CompletedNCT03002961

Indivior Inc.Opioid Use Disorder

Start: 2012-07-31End: 2013-10-31Updated: 2016-12-26

Phase 2

INDV-6001 Multiple-Dose Pharmacokinetic Study

CompletedNCT06576843

Indivior Inc.Moderate to Severe Opioid Use Disorder

Start: 2024-09-17End: 2026-01-21Updated: 2026-03-16

Phase 3

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

CompletedNCT02357901

Indivior Inc.Opioid Dependence, Opioid Related Disorders

Start: 2015-01-28End: 2016-04-29Updated: 2018-02-20

Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence

CompletedNCT02696096

Butler HospitalOpioid Addiction

Start: 2016-08-31End: 2020-02-29Updated: 2022-08-17

Phase 4

Houston Emergency Opioid Engagement System

Enrolling by invitationNCT03396276

The University of Texas Health Science Center, HoustonOpioid Use Disorder

Start: 2018-04-01End: 2030-08-31Target: 3000Updated: 2025-10-01

Unknown Phase

Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)

CompletedNCT00929253

Virginia Polytechnic Institute and State UniversityOpiate Addiction

Start: 2007-09-30End: 2010-04-30Updated: 2022-05-27

Providing Suboxone and PrEP Using Telemedicine

CompletedNCT04521920

Duke UniversityHiv, Opioid Use, Opioid-use Disorder +1

Start: 2020-11-09End: 2021-08-30Updated: 2023-06-09

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

CompletedNCT05108935

Duke UniversityHepatitis C, Hiv, Opioid Use +2

Start: 2022-02-17End: 2023-03-30Updated: 2023-04-27

2025-09-25

Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study

Harm Reduction Journal2024-03-268 citations

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.

2023-12-024 citations

18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.

2023-08-306 citations

Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation

Harm Reduction Journal2022-12-0318 citations

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

Frontiers in Pharmacology2022-11-1826 citations

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings

Journal of Addiction Medicine2022-09-1612 citations

Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.

2022-03-0910 citations

Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS.

2021-09-2422 citations

Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder.

2020-12-0732 citations

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

Journal of Addiction Medicine2020-03-1350 citations

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2019-02-18206 citations